Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MN-166 First · 1 trial · 2 indications
Participants are allowed to perform an operant task (click on a mouse) in order to receive a dose drug under investigation (oxycodone dose 0 mg, 15 mg, or 30 mg). The drug breakpoint is the maximum number of responses (mouse clicks) the participant was willing to make to receive the drug. Within the context of abuse liability studies, larger breakpoints represent greater abuse potential of a drug.
| Arm | Type | Description |
|---|---|---|
| MN-166 (formerly AV411) First | ACTIVE_COMPARATOR | Participants who began 14-day maintenance on MN-166 (50 mg) first, before switching to Placebo maintenance. |
| Placebo First | PLACEBO_COMPARATOR | Participants who began 14-day maintenance on Placebo first, before switching to MN-166 (50 mg) maintenance. |
| Name | Type | Description |
|---|---|---|
| MN-166 (50 mg) First | DRUG | In this arm of the study participants were first maintained on 50 mg MN-166 BID for approximately 14 days, and were then switched onto placebo maintenance. The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166). |
| Placebo First | DRUG | This arm of the study participants were first maintained on placebo for approximately 14 days, and were then switched onto 50mg MN-166 BID maintenance. . The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166). |
Inclusion Criteria: * Adults between the ages of 21 and 55 * Current opioid dependence according to DSM-IV criteria * currently not seeking treatment Exclusion Criteria: * Female patients that are currently pregnant, or breastfeeding. Lack of effective birth control. * Participants who have a pos...
MN-166 First is being studied for opioid abuse and opioid dependence. It was evaluated in a Phase 2 trial of 28 participants that examined oxycodone self-administration in people with opioid abuse. The drug is a small molecule developed by MediciNova, Inc. and has not been approved for this use.
MN-166 First is developed by MediciNova, Inc., which trades on the Nasdaq under the ticker MNOV. The company is the sponsor of the clinical program evaluating the drug in opioid abuse and opioid dependence.
MN-166 First is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are currently listed. The completed study enrolled 28 participants and was randomized, double-blind, and placebo-controlled.
MN-166 First has been studied in one completed Phase 2 trial, NCT01740414, titled Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers. The trial enrolled 28 adults aged 21 and older in the United States and included participants with opioid abuse or opioid dependence.